• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
AIDS Partnering 2009-2014 Product Image

AIDS Partnering 2009-2014

  • Published: March 2014
  • Region: Global
  • 1159 Pages
  • CurrentPartnering

FEATURED COMPANIES

  • Abbott
  • Baxter International
  • Dainippon Sumitomo
  • Grifols
  • Mitsubishi Tanabe
  • Servier
  • MORE

The AIDS Partnering 2009-2014 report provides understanding and access to the AIDS partnering deals and agreements entered into by the worlds leading healthcare companies.

- Trends in AIDS partnering deals
- Top AIDS deals by value
- Deals listed by company A-Z, industry sector, stage of development, technology type

The AIDS Partnering 2009-2014 provides understanding and access to the AIDS partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of AIDS partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors AIDS technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered READ MORE >

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in AIDS partnering

- 2.1. Introduction
- 2.2. AIDS partnering over the years
- 2.3. Bigpharma AIDS dealmaking activity
- 2.4. AIDS partnering by deal type
- 2.5. AIDS partnering industry sector
- 2.6. AIDS partnering by stage of development
- 2.7. AIDS partnering by technology type
- 2.8. Disclosed financial deal terms for AIDS partnering
- 2.8.1 AIDS headline values
- 2.8.2 AIDS upfront payments
- 2.8.3 AIDS milestone payments
- 2.8.4 AIDS royalty rates

Chapter 3 – Leading AIDS deals

- 3.1. Introduction
- 3.2. Top AIDS deals by value
- 3.3. Top AIDS deals involving bigpharma

Chapter 4 – Dealmaking directory

- 4.1. Introduction
- 4.2. Company A-Z
- 4.3. By deal type
- Asset purchase
- Bigpharma outlicensing
- Co-development
- Collaborative R&D
- Co-market
- Contract service
- Co-promotion
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Settlement
- Spin out
- Sub-license
- Supply
- Termination
- 4.4. By industry sector
- Academic
- Bigpharma
- Biotech
- Drug delivery
- Medical device
- Diagnostic
- Generic pharma
- Government
- Non-profit
- Pharmaceutical
- Research tools
- Services
- Specialty pharma
- 4.5. By stage of development
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Registration
- Marketed
- 4.6. By technology type
- Analysis
- Animal models
- Assays
- Bioinformatics
- Biological compounds
- Biomarkers
- Biomaterials
- Cell culture
- Cell therapy
- Clinical testing
- Diagnostic - companion
- Devices
- Diagnostics
- Discovery tools
- DNA probes
- Drug delivery
- Enabling technology
- Epigenetics
- Equipment
- Facilities
- Gene therapy
- Genomics
- Imaging
- Industrial chemicals
- In vitro models
- Monoclonal antibodies
- Nanotechnology
- Oligonucleotide
- Peptides
- Personalised medicine
- Processes
- Proteomics
- Radio/Chemo-therapy
- Recombinant DNA
- Research services
- Research supplies
- RNA therapeutics
- Screening
- Small molecules
- Stem cells
- Vaccines

Chapter 5 – Partnering resource center

- 5.1. Online partnering
- 5.2. Partnering events
- 5.3. Further reading on dealmaking

Appendices

- Appendix 1 – Deal type definitions

About Wildwood Ventures

- Current Partnering
- Current Agreements
- Recent titles from CurrentPartnering
- Order Form – Reports

Table of figures

- Figure 1: AIDS partnering since 2009
- Figure 2: Bigpharma – top 50 – AIDS deals 2009 to 2014
- Figure 3: Bigpharma AIDS deal frequency – 2009 to 2014
- Figure 4: AIDS partnering by deal type since 2009
- Figure 5: AIDS partnering by industry sector since 2009
- Figure 6: AIDS partnering by stage of development since 2009
- Figure 7: AIDS partnering by technology type since 2009
- Figure 8: AIDS deals with a headline value
- Figure 9: AIDS deals with upfront payment values
- Figure 10: AIDS deals with milestone payments
- Figure 11: AIDS deals with royalty rates, %
- Figure 12: Top AIDS deals by value since 2009
- Figure 13: Top AIDS deals signed by bigpharma value since 2009
- Figure 14: Online partnering resources
- Figure 15: Forthcoming partnering events
- Figure 16: Deal type definitions

The Immunology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the immunology partnering deals and agreements entered into by the worlds leading healthcare companies

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.

Abbott
Actavis
Actelion
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shionogi
Shire
Takeda
Teva
Valeant
Warner Chilcott
Watson

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos